Perspective Therapeutics, Inc. · LSX:A40EDR

Perspective Therapeutics, Inc. financial statements

Perspective Therapeutics, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2023FY2022FY2022FY2021FY2021FY2020FY2020
Revenue884.0K1.45M1.43M7.10M010.8M10.8M10.1M10.1M9.68M
Cost of revenue3.25M2.31M5.47M3.05M6.18M6.18M4.93M4.93M4.56M
Gross profit-2.37M-852.0K1.43M1.63M004.62M5.12M5.12M5.12M
Research and development84.2M41.6M21.3M2.60M881.0K850.0K2.58M1.43M1.43M1.13M
Selling, general and administrative30.2M26.6M21.0M10.9M9.35M6.62M9.43M4.69M4.69M4.57M
Operating income-113.6M-90.9M-40.9M-15.2M-8.67M-6.42M-7.39M-3.45M-3.44M-3.48M
Depreciation and amortization3.25M2.31M986.0K344.0K267.0K248.0K248.0K149.0K149.0K147.0K
EBITDA-110.3M-88.6M-40.0M-14.8M-8.40M-6.17M-7.14M-3.30M-3.29M-3.33M
Interest expense376.0K48.0K84.0K0050.0K30.0K
Income before tax-104.4M-80.4M-40.1M-14.7M-8.05M-6.30M-7.27M-3.39M-3.39M-3.45M
Income tax-793.0K-2.10M-2.65M000-199.0K0
Net income-103.1M-79.3M-46.5M-14.7M-10.8M-7.27M-7.27M-3.39M-3.19M-3.45M
Earnings per share, basic-1.40-1.23-1.74-0.10-0.08-0.05-0.51-0.03-0.06-0.05
Earnings per share, diluted-1.40-1.23-1.74-0.03-0.05

Balance sheet

LineFY2025FY2024FY2023FY2023FY2022FY2022FY2021FY2021FY2020FY2020
Cash and equivalents30.6M61.6M9.24M21.0M21.0M55.9M55.9M63.8M9.59M2.39M
Short-term investments114.1M165.3M022.8M22.8M0000
Receivables6.00K116.0K1.17M1.36M1.36M1.61M1.61M2.01M1.74M2.04M
Inventory1.41M1.41M1.40M1.40M980.0K665.0K645.0K
Current assets148.4M231.2M16.8M53.2M53.2M59.3M59.3M67.3M12.3M5.51M
Property, plant and equipment76.6M57.3M5.58M371.0K1.98M1.96M1.74M
Goodwill024.1M0
Total assets267.0M341.1M97.9M58.1M58.1M64.4M64.4M70.4M15.5M8.70M
Accounts payable20.5M10.3M6.91M1.54M1.54M966.0K966.0K730.0K494.0K654.0K
Current liabilities28.7M18.2M15.7M2.68M3.12M2.27M2.27M1.80M1.33M1.57M
Long-term debt1.57M1.63M1.68M
Total debt1.63M1.68M1.73M524.0K524.0K776.0K897.0K1.00M
Total liabilities59.9M50.4M22.7M3.45M3.45M3.16M3.16M3.01M2.74M2.98M
Shareholders' equity207.0M290.7M75.2M54.6M54.6M61.3M61.3M67.4M12.8M5.72M
Shares outstanding74.3M70.7M28.2M142.1M142.1M142.0M14.2M141.9M54.9M68.9M

Cash flow

LineFY2025FY2024FY2023FY2023FY2022FY2022FY2021FY2021FY2020FY2020
Cash from operations-82.5M-18.3M-36.9M-12.2M-10.4M-7.71M-7.71M-2.84M-2.84M-3.64M
Capital spending-12.7M-54.4M-1.07M-302.0K-282.0K-266.0K-266.0K-381.0K-381.0K-273.0K
Free cash flow-95.2M-72.7M-38.0M-12.5M-10.7M-7.98M-7.98M-3.22M-3.22M-3.91M
Cash from investing41.2M-218.9M24.4M-29.0M-284.0K-410.0K-410.0K-287.0K
Cash from financing10.3M289.4M785.0K56.0K28.0K56.0K56.0K64.7M64.7M994.0K
Dividends paid00-9.00K-9.00K-11.0K
Change in cash-31.0M52.2M-11.8M182.0K-39.4M-7.94M-7.94M61.4M61.4M-2.93M